These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3126703)

  • 1. Characterization and comparison of two penicillinase-producing strains of Streptococcus (Enterococcus) faecalis.
    Patterson JE; Masecar BL; Zervos MJ
    Antimicrob Agents Chemother; 1988 Jan; 32(1):122-4. PubMed ID: 3126703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis.
    Lavoie SR; Wong ES; Coudron PE; Williams DS; Markowitz SM
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1447-51. PubMed ID: 8363374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin.
    Murray BE; Mederski-Samoraj B; Foster SK; Brunton JL; Harford P
    J Clin Invest; 1986 Jan; 77(1):289-93. PubMed ID: 3080475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
    Hoellman DB; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Apr; 42(4):857-61. PubMed ID: 9559796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis.
    Murray BE; Mederski-Samaroj B
    J Clin Invest; 1983 Sep; 72(3):1168-71. PubMed ID: 6411768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible prevention of in vitro selection of resistant Streptococcus pneumoniae by beta-lactamase inhibitors.
    Carsenti-Etesse H; Durant J; De Salvador F; Bensoussan M; Bensoussan F; Pradier C; Bernard E; Mondain V; Thabaut A; Dellamonica P
    Eur J Clin Microbiol Infect Dis; 1994 Dec; 13(12):1058-62. PubMed ID: 7889969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-kill kinetic studies of ampicillin/sulbactam for beta-lactamase-producing enterococci.
    Patterson JE; Farrel P; Zervos MJ
    Diagn Microbiol Infect Dis; 1991; 14(6):495-9. PubMed ID: 1802536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins.
    McDougal LK; Thornsberry C
    J Clin Microbiol; 1986 May; 23(5):832-9. PubMed ID: 3011847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
    Schick DG; Canawati HN; Montgomerie JZ
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):233-9. PubMed ID: 9458980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
    Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J
    Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains.
    Paniagua GL; Monroy E; García O; Vaca S
    Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level resistance to gentamicin in clinical isolates of enterococci.
    Mederski-Samoraj BD; Murray BE
    J Infect Dis; 1983 Apr; 147(4):751-7. PubMed ID: 6404994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sulbactam and clavulanic acid: studies of enzyme kinetics and synergism with ampicillin and mezlocillin].
    Cullmann W; Binder S; Stieglitz M
    Immun Infekt; 1987 May; 15(3):103-9. PubMed ID: 3038733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobilization of the penicillinase gene in Enterococcus faecalis.
    Chow JW; Perri MB; Thal LA; Zervos MJ
    Antimicrob Agents Chemother; 1993 May; 37(5):1187-9. PubMed ID: 8517713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two beta-lactamase-producing strains of Streptococcus faecalis.
    Murray BE; Church DA; Wanger A; Zscheck K; Levison ME; Ingerman MJ; Abrutyn E; Mederski-Samoraj B
    Antimicrob Agents Chemother; 1986 Dec; 30(6):861-4. PubMed ID: 3028251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin.
    Moellering RC; Wennersten C; Weinstein AJ
    Antimicrob Agents Chemother; 1973 Apr; 3(4):526-9. PubMed ID: 4208292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro comparison of the beta lactamase-inhibitory action of clavulanic acid and sulbactam in ampicillin-resistant enterobacteria].
    Grimm H
    Arzneimittelforschung; 1987 Oct; 37(10):1116-9. PubMed ID: 3501722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
    Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.